RxDoctor Payments Data

Charles Alpers

Anatomic Pathology & Clinical Pathology · Seattle, WANPI 1922188820

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $115,250 of the $131,375 with a category attached, or 87.7%. Astrazeneca UK Limited accounts for 76.7% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $50,764, 2.7 times the $19,075 reported in 2019. Among anatomic pathology & clinical pathology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$131,375in general payments, 2019–2025

Across 49 payments — averaging $2681.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$101K
  • Travere Therapeutics, Inc.$28K
  • Novartis$3K
$86,224in research payments, 2019–2025

Across 3 payments — averaging $28,741 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim$69K
  • Astrazeneca UK Limited$17K

What the payments were for

  • Consulting fees$115,25088%
  • Speaking & faculty fees$9,0007%
  • Travel & lodging$5,5184%
  • Food & beverage$1,6071%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astrazeneca UK Limited14$100,825
Travere Therapeutics, Inc.30$27,537
Novartis5$3,013

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$131,375 in reported general payments places this provider in the 95th percentile of 119 anatomic pathology & clinical pathology providers in Washington.

See all anatomic pathology & clinical pathology providers in Washington

Medicare billing

Part B allowed, 2024
$5,360
Medicare patients
14
Services billed
175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other anatomic pathology & clinical pathology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →